Tryptophanol-Derived Oxazolopyrrolidone Lactams as Potential Anticancer Agents against Gastric Adenocarcinoma

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Gastric cancer is a leading cause of cancer-related mortality.
• Targeting the tumor suppressor protein p53 is a key strategy in cancer therapy.
• Tryptophanol-derived polycyclic compounds have previously shown potential in activating p53.

Purpose of the Study:

• To develop novel, enantiomerically pure tryptophanol-derived small molecules for targeting human gastric adenocarcinoma (AGS) cells.
• To identify compounds with selectivity for gastric cancer cells over other cancer types.
• To investigate the mechanism of action and metabolic stability of these novel compounds.

Main Methods:

• Screening of fourteen tryptophanol-derived compounds against AGS cells.
• Optimization of a hit compound to develop selective derivatives.
• Evaluation of compound toxicity in normal HEK 293T cells and other cancer cell lines (MDA-MB-231, A-549, DU-145, MG-63).
• Apoptosis assays to determine the mechanism of growth inhibition.
• In vitro stability studies using human plasma and liver microsomes.

Main Results:

• Two novel tryptophanol derivatives demonstrated selectivity for AGS gastric cells.
• The compounds exhibited non-toxicity towards normal HEK 293T cells.
• Growth inhibition of AGS cells was confirmed to be mediated by apoptosis.
• The developed compounds showed stability in human plasma and liver microsomes, with major metabolic pathways identified as indole ring hydroxylation.

Conclusions:

• Enantiomerically pure tryptophanol-derived small molecules represent a promising new class of therapeutics for gastric cancer.
• The identified compounds display selective toxicity towards gastric adenocarcinoma cells and induce apoptosis.
• These compounds possess favorable stability and metabolic profiles, warranting further investigation for clinical application.